Ultrasound Responsive Nanoparticles in Cancer Imaging and Therapy

Rawan A Fitaihi* and Alanoud Mohammed Altalal

Department of pharmaceutics, King Saud University, Saudi Arabia

Received: February 23, 2018; Published: March 05, 2018

*Corresponding author: Rawan A Fitaihi, King Saud University, college of pharmacy, Department of pharmaceutics, Riyadh, Saudi Arabia,
Tel: 966-559333388, Email: rfitaihi@ksu.edu.sa

Abstract

Ultrasound-responsive nanoparticle can selectively target cancer cell by applying ultrasound waves at the desired part, minimizing unwanted effect and improving the efficacy of anticancer agent. In this review we summarize the recent application of ultrasound responsive nanoparticles for imaging and therapy.

Keyword: Cancer; Ultrasound; Nanobubbles; Stimuli-responsive

Abbreviations: DPPC: Di-Palmitoylsn-Glycero-3-Phosphocholine; MPPC: Myristoyl-2-Palmitoyl-sn-Glycero-3-Phosphocholine; MSPC: Myristoyl-2-Stearoyl-sn-Glycero-3-Phosphocholin; PFC: Per Fluoro Carbon; VEGFR2: Vascular Endothelial Growth Factor Receptor 2; ERP: Enhanced Permeation and Retention Effect

Introduction

Over the years, tremendous efforts have been made to improve cancer diagnosis and treatment. Delivering anticancer agents to solid tumors has always been a major challenge. Anticancer agents have no tumor selectivity, making them potentially toxic to cancer and normal cells. Moreover, tumor tissue has abnormal vasculature and disrupted extracellular matrix which may act as a drug barrier and limit drug bioavailability [1]. Introduction of nanotechnology has shown promising results to overcome the inconsistent pharmacokinetics and distribution of anticancer agents. The use of nanoscale formulations can help to improve drug in-vivo pharmacokinetics, increase their stability and minimize degradation, thus more drug accumulation inside the tumor by the so called enhanced permeation and retention effect (ERP) [2]. Another strategy to target cancer cell is to use stimuli-responsive nanosystems. This “smart” technology is sensitive to either external stimuli, such as light, magnetic field, ultrasound, etc. or internal stimuli that take advantage of tumor microenvironment characteristics Such as lower pH value, higher temperature, etc.

External stimuli-responsive systems could be used as contrast agents to enhance nanoparticles accumulation in the target tissues, by activating the nanosystems with external triggers at the desired time. Therefore, more controlled drug release and higher potential for clinical efficiency [3]. Ultrasound technology is one of the most widely used diagnostic modalities in clinics, due to its good safety profile and relatively inexpensive application. Ultrasound-responsive nanosystems are used to control drug release and to direct it toward tumor cells upon the application of ultrasound waves.

Ultrasound-Responsive Nano-System

The drugs are released from the nanosystems through thermal and mechanical effects produced by ultrasound. Thermo responsive liposome’s or polymer micelles were formulated to release their drug payload after mild application of heat (typically around 40-42 °C) on the tumor allowing rapid release of the drug and deeper penetration inside the tumor. 1,2-dipalmitoylsn-glycero-3-phosphocholine (DPPC) is the most frequently used phospholipid for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery. With a melting temperature just above body temperature (41.5 °C), applying mild hyperthermia on the formulation will render more flexible and permeable liposome for thermal drug delivery.
at different ratios to change the release rate [5]. ThermoDox® is referenced in many clinical trials uses lysolipid thermo sensitive liposome technology to encapsulate doxorubicin [6].

Liposomes have also been used for ultrasound imaging by enclosing air within the phospholipid bilayer. When ultrasound was applied the Liposomes, structure was fragmented and the entrapped gas bubbles diffused out of the phospholipid [7]. Nanobubbles are gas in liquid emulsions with polyalycic acid shell to stabilize the Nanobubbles. While Per fluorocarbon (PFC) nanodroplets are liquid in liquid emulsions that under sufficient ultrasound pressures can be vaporized in situ to produce gas bubbles. The liquid to gas transition results in an immediate 3 to 5 times diameter expansion [8]. Chen et al. formulated ligand directed camptothecin loaded acoustic nanodroplets in mouse xenograft tumor models; the nanodroplets successfully enhanced antitumor effect and ultrasound imaging [9]. Another strategy to design nanoscale bubble is to use solid nanoparticles. Amorphous hydrophobic solid substances can entrap gas in their pores. Jin et al. prepared mesoporous silica nanoparticles with different levels of hydrophobicity and large surface areas; super hydrophobic mesoporous silica nanoparticles were able to generate micro bubbles in situ [10].

Targeting Techniques

Targeted delivery with ultrasound responsive nanoparticles can deliver chemotherapeutic agent or gene therapy specifically to tumor cells with the aid of different targeting ligands conjugated to the surface of the nanoparticles. This ligand can be attached covalently or non-covalently to the surface of the ultrasound responsive nanoparticles. In ultrasound imaging, many experimental studies employ streptavidin/biotin non-covalent interaction for binding the shell of the Nanobubbles with targeting ligand. This conjugation cannot be employed in human since streptavidin is immunogenic. Willmann et al. have developed a dual-targeted ultrasound imaging agent with attaching anti-VEGFR2, anti-αvβ3 integrin to Nanobubbles by streptavidin/biotin interaction, the signal intensity noticeably improved in vivo imaging of tumor angiogenesis in a human ovarian cancer xenografting [11]. Covalent signal intensity noticeably improved for imaging tumor angiogenesis in a human ovarian cancer xenografting [11]. Covalent binding targeting methods depend on the type of functional groups exposed on the surface of the ultrasound responsive nanocarriers. The BR55 compound (Bracco) is an ultrasound contrast agent that does not rely on biotin/streptavidin binding approach or an antibody for binding. BR55 is a vascular endothelial growth factor receptor 2 (VEGFR2) targeted ultrasound contrast agent for molecular imaging. It’s currently in phase 0 clinical exploratory study to test its safety and possibility to be used for the detection of prostate cancer [12].

For therapeutic effect, ultrasound contrast agents are either destroyed by cavitation or thermally heated in order to release the drug or gene payload. VanOsdol et al. formulated Nanobubbles encapsulated thermo sensitive Liposomes loaded with doxorubicin. With regional administration of HIFU for short duration, doxorubicin delivery into solid tumors from thermo sensitive liposome’s was improved, and gas encapsulation allowed Dox to penetrate the tumor core, and the mechanisms controlling such transport involve the synergistic effect of reduced tissue barriers and hyperthermia [13]. Gene delivery approach is recently employed in many preclinical studies. Xie et al. [14] developed Cell-penetrating peptide siRNA conjugate entrapped in an ephrin mimetic peptide modified Nanobubbles. An ephrin mimetic peptide (YSA peptide) was used due to its high efficiency in targeting EphA2 positive tumor cells. The entrapped CPP-siRNA was released after Nanobubbles shell fragmentation by the effect of ultrasound cavitation [14].

Ultrasound-Induced Drug Delivery

Encapsulation of nanoparticle with gas renders the particles acoustically active. Ultrasound responsive particles are either grow and collapse by high-pressure ultrasound to release drug payload through microjet or expand and contract by lower pressure ultrasound pulse, massaging the vascular wall. Thus increasing the blood vessel permeability and improving the extravasation of administered drugs [15]. A phase 1 clinical trial utilized the commercially available phospholipid micro bubble (SonoVue®) to enhance the therapeutic efficacy of chemotherapeutic agent gemcitabine. Application of ultrasound allows direct contact between endothelial cells and the micro bubbles, increasing intracellular stress signaling and drug sensitivity, which resulted in improved gemcitabine response in cancer patient [16].

Conclusion

Application of ultrasound wave on biological tissue can produce mechanical effect or thermal effect that can be utilized in deferent ways. Many preclinical studies have shown that ultrasound responsive nanoparticles could play an important role in early cancer detection and continuous cancer assessment. Moreover, the use of targeted and non-targeted ultrasound responsive nanoparticle for drug and gene delivery is expected to find its clinical application.

References

1. Galmarini C, Galmarini F (2003) Multidrug resistance in cancer therapy: role of the microenvironment. Curr Opin Investig Drugs 4(12): 1416-1421.
2. Maeda H (2015) Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Advanced Drug Delivery Reviews 91(Suppl C): 3-6.
3. Yao J, Feng J, Chen J (2016) External-stimuli responsive systems for cancer theranostic. Asian Journal of Pharmaceutical Sciences 11(5): 585-595.
4. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R (1978) Design of liposomes for enhanced local release of drugs by hyperthermia. science 202(4374): 1290-1293.
5. Mills JK, Needham D (2005) Lysolipid incorporation in dipalmitoyl phosphatidyl choline bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition. Biochimica et Biophysica Acta (BBA) - Biomembranes 1716(2): 77-96.
6. Wood BJ, Poon RT, Locklin JK, Dreher MR, Ng KK, et al. (2012) Phase 1 study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J Vasc Interv Radiol 23(2): 248-255.
7. Smith DAB, Vaidya SS, Kopechek JA, Huang SL, Klegerman ME, et al. (2010) Ultrasound-Triggered Release of Recombinant Tissue-Type Plasminogen Activator from Echogenic Liposomes. Ultrasound in Medicine and Biology 36(1): 145-157.

8. Kripfgans OD, Fowlkes JB, Miller DL, Eldevik, OP, Carson PL. (2000) Acoustic droplet vaporization for therapeutic and diagnostic applications. Ultrasound in Medicine & Biology 26(7): 1177-1189.

9. Chen WT, Kang ST, Lin JL, Wang CH, Chen RC, et al. (2015) Targeted tumor theranostics using folate-conjugated and camptothecin-loaded acoustic nanodroplets in a mouse xenograft model. Biomaterials 53(Suppl C): 699-708.

10. Qin Q, Lin CY, Kang ST, Chang YC, Zheng H, et al. (2017) Superhydrophobic silica nanoparticles as ultrasound contrast agents. Ultrasound Sonochemistry 36(Suppl C): 262-269.

11. Willmann JK, Lutz AM, Paulmurugan R, Patel MR, Chu P, et al. (2008) Dual-targeted Contrast Agent for US Assessment of Tumor Angiogenesis in Vivo. Radiology 248(3): 936-944.

12. Smeenge M, Tranquart F, Mannaerts CK, de Reijke TM, Van de Vijver, et al. (2017) First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study. Investigative Radiology 52(7): 419-427.

13. Van Osdol J, Ektate K, Ramasamy S, Maples D, Collins W, et al. (2017) Sequential HIFU heating and nanobubble encapsulation provide efficient drug penetration from stealth and temperature sensitive liposomes in colon cancer. Journal of controlled release 247(Suppl C): 55-63.

14. Xie X, Yang Y, Lin W, Liu H, Liu H, et al. (2015) Cell-penetrating peptide-siRNA conjugate loaded YSA-modified nanobubbles for ultrasound triggered siRNA delivery. Colloids and Surfaces B: Biointerfaces 136(Suppl C): 641-650.

15. Pitt WG, Husseini GA, Staples BJ (2004) Ultrasonic drug delivery—a general review. Expert Opinion on Drug Delivery 1(1): 37-56.

16. Dimcevski G, Kotopoulos S, Bjønes T, Hoem D, Schjøtt J, et al. (2016) A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of controlled release 243(Suppl C): 172-181.